http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2587752-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e9a38b33890e9b90bb35e723639d4968 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2015-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3708acfb61b34aa0d36a14646521ad06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd2d80ac663911372d4f4c84b1c0b470 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00663de8e0de4ad4524bda474056af40 |
| publicationDate | 2016-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2587752-C1 |
| titleOfInvention | Method for evaluation of treatment effectiveness in cardiac patients with heparin-induced thrombocytopenia |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to medicine, particularly to cardiac surgery, and may be used for laboratory evaluation of treatment effectiveness fondaparinux in cardiac patients with heparin-induced thrombocytopenia. Method comprises: cardiac surgery in patients with heparin-induced thrombocytopenia fondaparinux is administered subcutaneously 1 time per day at a dose of 2.5-7.5 mg, and 3 hours after administration determining residual activity of factor Xa and antithrombin III activity in blood plasma. When residual activity of Xa is in range of 0.4-0.7 mg/ml and antithrombin III activity is in range of 60-120 % fondaparinux therapy is effective - no risk of bleeding or thrombosis. When residual Xa activity is below 0.4 mg/ ml and activity of antithrombin III is in range of 60-120 % fondaparinux therapy is not effective - a high risk of thrombosis, increase in dose of fondaparinux is recommended. When Xa residual activity is below 0.4 mg/ml and antithrombin III activity is below 60 %, fondaparinux is not effective - high risk of thrombosis, it is recommended to increase activity of antithrombin III in plasma by administering fresh frozen plasma or antithrombin preparations. When Xa residual activity is above 0.7 mg/ml and activity of antithrombin III is in range of 60-120 % fondaparinux therapy is not effective - high risk of bleeding, it is recommended to decrease dose of fondaparinux. n EFFECT: invention is aimed at improving efficiency of treatment of fondaparinux in cardiac surgical patients with heparin-induced thrombocytopenia. n 1 cl, 2 ex |
| priorityDate | 2015-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.